You are here: Industry Insights > BioVersys

News List

EU to support novel antibiotics with €20 million funding europeanpharmaceuticalreview
April 15, 2021
BioVersys will receive €20 million in funding to support its development of new treatments for antimicrobial resistant infections.
BioVersys Gets EIB Funds to Address Antimicrobial Resistance contractpharma
April 15, 2021
The European Investment Bank (EIB) and BioVersys AG, a clinical-stage pharmaceutical company developing treatments for multidrug-resistant bacterial infections, signed a €20 million venture debt transaction.
BioVersys Announces CHF 19 Million Financing to Advance Novel AMR Candidates into Clinical Development b3cnewswire
September 01, 2020
BioVersys announces the successful completion of a CHF 19 million Series B financing round to advance its two lead assets of infectious disease candidates into first in human clinical trials and has also strengthened its board with the appointment of Dr.
BioVersys Receives CARB-X Award of up to US$ 8.92 Million for Development of Novel Antimicrobial Therapies b3cnewswire
October 30, 2019
BioVersys AG, a privately owned, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in ...